Antibody response, neutralizing potency, and transplacental antibody transfer following SARS-CoV-2 infection versus mRNA-1273, BNT162b2 COVID-19 vaccination in pregnancy.
SARS-CoV-2
pregnancy
reproductive immunity
vaccine
Journal
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
ISSN: 1879-3479
Titre abrégé: Int J Gynaecol Obstet
Pays: United States
ID NLM: 0210174
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
revised:
16
11
2022
received:
10
06
2022
accepted:
22
12
2022
medline:
19
6
2023
pubmed:
5
1
2023
entrez:
4
1
2023
Statut:
ppublish
Résumé
To improve our understanding of the immune response, including the neutralization antibody response, following COVID-19 vaccination in pregnancy. This was a prospective cohort study comprising patients with PCR-confirmed SARS-CoV-2 infection and patients who received both doses of mRNA COVID-19 vaccine (mRNA-1273, BNT162b2) in pregnancy recruited from two hospitals in Atlanta, GA, USA. Maternal blood and cord blood at delivery were assayed for anti-receptor binding domain (RBD) IgG, IgA and IgM, and neutralizing antibody. The detection of antibodies, titers, and maternal to fetal transfer ratios were compared. Nearly all patients had detectable RBD-binding IgG in maternal and cord samples. The vaccinated versus infected cohort had a significantly greater proportion of cord samples with detectable neutralizing antibody (94% vs. 28%, P < 0.001) and significantly higher transfer ratios for RBD-specific IgG and neutralizing antibodies with a transfer efficiency of 105% (vs. 80%, P < 0.001) and 110% (vs. 90%, P < 0.001), respectively. There was a significant linear decline in maternal and cord blood RBD-specific IgG and neutralizing antibody titers as time from vaccination to delivery increased. Those who receive the mRNA COVID-19 vaccine mount an immune response that is equivalent to-if not greater than-those naturally infected by SARS-CoV-2 during pregnancy.
Substances chimiques
2019-nCoV Vaccine mRNA-1273
EPK39PL4R4
BNT162 Vaccine
0
COVID-19 Vaccines
0
Antibodies, Neutralizing
0
RNA, Messenger
0
Immunoglobulin G
0
Antibodies, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
154-162Subventions
Organisme : NIAID NIH HHS
ID : P30 AI050409
Pays : United States
Organisme : ODCDC CDC HHS
ID : P51 OD011132
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI050409
Pays : United States
Organisme : ODCDC CDC HHS
ID : P51 OD011132
Pays : United States
Informations de copyright
© 2023 International Federation of Gynecology and Obstetrics.
Références
Zambrano LD, Ellington S, Strid P, et al. Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status - United States, January 22-October 3, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1641-1647.
Seasely AR, Blanchard CT, Arora N, et al. Maternal and perinatal outcomes associated with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta (B.1.617.2) variant. Obstet Gynecol. 2021;138:842-844.
Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603-2615.
Dagan N, Barda N, Biron-Shental T, et al. Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy. Nat Med. 2021;27:1693-1695.
American College of Obstetricians and Gynecologists. Vaccinating pregnant and lactating patients against COVID-19: practice advisory-November 2021. Available at: https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/12/vaccinating-pregnant-and-lactating-patients-against-covid-19. Accessed 22 November 2021.
Royal College of Obstetricians and Gynecologists. Coronavirus infection and Pregnancy. Available at: https://www.rcog.org.uk/en/guidelines-research-services/guidelines/coronavirus-pregnancy/covid-19-virus-infection-and-pregnancy/#vaccines. Accessed 13 December 2021.
Collier A-RY, McMahan K, Yu J, et al. Immunogenicity of COVID-19 mRNA vaccines in pregnant and lactating women. JAMA. 2021;325:2370-2380.
Gray KJ, Bordt EA, Atyeo C, et al. Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study. Am J Obstet Gynecol. 2021;225:303.e1-303.e17.
Prabhu M, Murphy EA, Sukhu AC, et al. Antibody response to coronavirus disease 2019 (COVID-19) messenger RNA vaccination in pregnant women and transplacental passage into cord blood. Obstet Gynecol. 2021;138:278-280.
Mithal LB, Otero S, Shanes ED, Goldstein JA, Miller ES. Cord blood antibodies following maternal coronavirus disease 2019 vaccination during pregnancy. Am J Obstet Gynecol. 2021;225:192-194.
Nir O, Schwartz A, Toussia-Cohen S, et al. Maternal-neonatal transfer of SARS-CoV-2 immunoglobulin G antibodies among parturient women treated with BNT162b2 messenger RNA vaccine during pregnancy. Am J Obstet Gynecol MFM. 2021;4:100492.
Rottenstreich A, Zarbiv G, Oiknine-Djian E, Zigron R, Wolf DG, Porat S. Efficient maternofetal transplacental transfer of anti- severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike antibodies after antenatal SARS-CoV-2 BNT162b2 messenger RNA vaccination. Clin Infect Dis. 2021;73:1909-1912.
Beharier O, Plitman Mayo R, Raz T, et al. Efficient maternal to neonatal transfer of antibodies against SARS-CoV-2 and BNT162b2 mRNA COVID-19 vaccine. J Clin Invest. 2021;131:e150319.
Trostle ME, Aguero-Rosenfeld ME, Roman AS, Lighter JL. High antibody levels in cord blood from pregnant women vaccinated against COVID-19. Am J Obstet Gynecol MFM. 2021;3:100481.
Joseph NT, Dude CM, Verkerke HP, et al. Maternal antibody response, neutralizing potency, and placental antibody transfer after severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection. Obstet Gynecol. 2021;138:189-197.
Verkerke H, Horwath M, Saeedi B, et al. Comparison of antibody class-specific SARS-CoV-2 serologies for the diagnosis of acute COVID-19. J Clin Microbiol. 2021;59:e02026-20.
Verkerke H, Saeedi BJ, Boyer D, et al. Are we forgetting about IgA? A Re-examination of coronavirus disease 2019 convalescent plasma. Transfusion. 2021;61:1740-1748.
Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol. 2012;2012:985646.
Albrecht M, Arck PC. Vertically transferred immunity in neonates: mothers, mechanisms and mediators. Front Immunol. 2020;11:555.
Razzaghi H, Meghani M, Pingali C, et al. COVID-19 vaccination coverage among pregnant women during pregnancy - eight integrated health care organizations, United States, December 14, 2020-may 8, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:895-899.
Kerekes S, Ji M, Shih S-F, et al. Differential effect of vaccine effectiveness and safety on COVID-19 vaccine acceptance across socioeconomic groups in an international sample. Vaccines (Basel). 2021;9:9.
Goldfarb IT, Little S, Brown J, Riley LE. Use of the combined tetanus-diphtheria and pertussis vaccine during pregnancy. Am J Obstet Gynecol. 2014;211(299):e1-e5.
Healy CM, Ng N, Taylor RS, Rench MA, Swaim LS. Tetanus and diphtheria toxoids and acellular pertussis vaccine uptake during pregnancy in a metropolitan tertiary care center. Vaccine. 2015;33:4983-4987.
Lutz CS, Carr W, Cohn A, Rodriguez L. Understanding barriers and predictors of maternal immunization: identifying gaps through an exploratory literature review. Vaccine. 2018;36:7445-7455.
Myers KL. Predictors of maternal vaccination in the United States: an integrative review of the literature. Vaccine. 2016;34:3942-3949.